Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From WuXi AppTec
Several Chinese biotech developments during the Lunar New Year break have put investors on high alert, namely the continued share price slide of Chinese biotech bellwether WuXi Apptec, Lianbio ceasing operations and I-Mab divesting its China business to become a fully US-focused company.
A draft bill from the US House related to national security issues sent WuXi Biologics' shares tumbling over concerns around increased US scrutiny of Chinese firms, which a company clarification did little to dispel.
In 2024, Sun Pharma’s ADC candidate is expected to be in human trials, while CDMOs like Piramal Pharma Solutions and Aurigene are to operationalize significant new capacities. But can India compensate for a late start on the ADC journey by tapping low development costs and favorable policies, or is it too little with China far ahead in the race?
Brian Scanlan, operating partner (life sciences), Edgewater Capital Partners, in an interview with Scrip, outlines where things may be headed in the CRO/CDMO segment amid big pharma streamlining efforts, “belt tightening” by emerging biopharma, down rounds and heightened geopolitical tension.
- Contract Research Organization-CRO
- Laboratory Testing Services
- Medical Devices
Drug Discovery Technologies
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Crelux GmbH
- Faxian Therapeutics
- JW Biotechnology (Shanghai) Co., Ltd
- ResearchPoint Global
- STA Pharmaceutical Co., Ltd.
- WuXi PharmaTech
- WuXi Merger Limited
- XenoBiotic Laboratories, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.